Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with